Zometa

Information about osteonecrosis of the jaw onj ; , in patients who have received zometa or aredia r ; pamidronate disodium for injection ; as a component of their therapy.

Another protease. This may be behind the poor ability of spermatids from patients with complete spermiogenesis failure to activate human oocytes Tesarik et al., 1998 ; , in comparison with the performance of round spermatids recovered from men with normal spermatogenesis Sousa et al., 1996 ; . Poor fertilization rates with the use of spermatids from patients with complete spermiogenesis failure have, indeed, been reported Vanderzwalmen et al., 1997 ; . In conclusion, apoptosis is a frequent phenomenon in germ cells from patients with spermatogenic disorders, especially in those suffering from complete spermiogenesis failure. Because a reliable clinical and histopathological diagnosis of complete spermiogenesis failure is not available, mainly because of the possible persistence of small foci of complete spermatogenesis that may not be sampled during a diagnostic biopsy and whose output may not be sufficient for spermatozoa to reach the ejaculate, a direct evaluation of germ cell apoptosis offers an easier and more straightforward approach. One of the methods described in this study, combining a standard TUNEL assay with immunodetection of a specific germline marker, has the advantage of being applicable both to cell smears prepared from disintegrated testicular tissue and to ejaculated cells. The latter might provide a preferrable screening method with which preliminary information can be obtained without the need for an invasive sampling technique.

In vitro studies indicate that zoledronic acid is approximately 22% bound to plasma proteins. In vitro studies also indicate that zoledronic acid does not inhibit microsomal CYP450 enzymes. In vivo studies showed that zoledronic acid is not metabolized, and is excreted into the urine as the intact drug. However, no in vivo drug interaction studies have been performed. 7.1 Aminoglycosides Caution is advised when bisphosphonates are administered with aminoglycosides, since these agents may have an additive effect to lower serum calcium level for prolonged periods. This effect has not been reported in Zomeat clinical trials. 7.2 Loop Diuretics Caution should also be exercised when Zomeat is used in combination with loop diuretics due to an increased risk of hypocalcemia. 7.3 Nephrotoxic Drugs Caution is indicated when Zome6a is used with other potentially nephrotoxic drugs. 7.4 Thalidomide In multiple myeloma patients, the risk of renal dysfunction may be increased when Zzometa is used in combination with thalidomide. 8. USE IN SPECIFIC POPULATIONS 8.1 Pregnancy ZOMETA SHOULD NOT BE USED DURING PREGNANCY. There are no studies in pregnant women using Zometa. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant [see Warnings and Precautions 5.4 ; ] and lamictal.
Evaluated in that setting. However, if your kidney function is irreversibly damaged-- that is, you are permanently on dialysis, you can receive Zoometa or Aredia every 3 to 4 weeks at standard dosing and infusion times, Aredia at 90 mg over 2 hours or Zometa at 4 mg every 15 minutes, just as you would if your kidney function were normal. The reason that's true is that this drug immediately goes into the bone, and it stays there. So, you don't have to worry about damage in a patient on dialysis as long as they don't get that drug right before the dialysis procedure. Also of note, if your myeloma is causing kidney problems at the beginning--that is if you're newly diagnosed and your kidneys are poor--we usually hold off on the bisphosphonates for several months hoping that we can return the kidney function to normal. We don't want to give any drug that potentially can affect the kidneys. The exceptions to that would be two-fold: 1 ; if you have severe bone disease, and, 2 ; if your calcium is high at diagnosis. If your calcium is high at the time of diagnosis, we want to get that calcium back to normal as quickly as possible because that high calcium may be contributing to the kidney problem. In that regard, studies comparing Zometa and Aredia suggest that Zometa can do this more quickly and more efficiently--that is, more patients will reverse their calcium with the newer bisphosphonate than with Aredia. In the setting of high calcium, Zometa is the drug of choice. Now let's turn our attention to the most controversial, new complication we've observed in the long-term use of bisphosphonates, oral or IV, and that is called osteonecrosis of the jaw ONJ ; . ONJ involves the loss of vital function of the jawbones. The mandible, the lower jaw, and sometimes the upper jaw or maxilla, will actually die, and it will be exposed. You lose the covering, the mucosal covering, and you will have exposed, dead bone. That's kind of the definition. It doesn't heal over a number of weeks. The incidence of this is approximately 1% per year of exposure to the drug. However, it is important to recognize that this occurs with varying degrees of severity. Now, to minimize that risk if you're new [to using] bisphosphonates or you've been on them for some time you must maintain excellent oral hygiene.That is your best prophylaxis. It is also important to not use tobacco, which certainly does increase your risk, and not abuse alcohol. Now, your oncologist should be telling you, however, if you haven't started these drugs yet to get a proper dental exam. Any extensive dental procedures, such as extractions or implants, should be done before you start these drugs. Once you're on them, you should avoid any of these types of procedures if at all possible. [I like to suggest to] make sure you get a second opinion before you get a dental extraction if you're on an IV bisphosphonate.
It is not known whether Zometa is excreted in human milk. Because many drugs are excreted in human milk, and because Zometa binds to bone long-term, Zometa should not be administered to a nursing woman and nitrofurantoin.

Occurred following tooth extraction where there would be complications including delayed wound healing. About onethird of patients presented with spontaneous eruption of a piece of bone near their teeth. As a result of these findings, I strongly recommend that patients receive a thorough dental exam prior to beginning bisphosphonate therapy, and certainly prior to a second dose. If it is absolutely necessary to have a tooth pulled, it should be done prior to starting bisphosphonates, or before the second dose. Patients on bisphosphonates should be discouraged from having elective oral surgery, and need to talk to Mary or Christine, my Physician Assistants, prior to scheduling any dental work. As my paper explains later, root canals are considered the treatment of choice, and then just allowing a tooth to fall out. For your safety, please do not allow a tooth to be pulled without our clearance. Novartis, the manufacturer of Zometa and Aredia, noted that as of December 2004, 119 cases of ONJ had developed among 1.9 million patients treated with Aredia, and 248 cases in 1 million patients treated with Zometa worldwide. Their most recent count of 875 ONJ case reports represented only 0.0003% of the 2.9 million patients treated with the two Novartis drugs, although they did admit this likely represented an underestimate of all cases. Interestingly, in a review of 4, 032 patients treated at M.D. Anderson Hospital, of the first 963 charts reviewed, ONJ occurred in 18 of 780 patients, with one of the following three cancers: breast 11 multiple myeloma 6 ; , and thyroid 1 ; . No cases were reported among patients with other cancers, including prostate, and several other cancers. The M.D. Anderson doctor concluded that the balance of benefit to risk for Zometa and Aredia remains favorable. Dr. Bob and Compassionate Oncology Medical Group reduced the frequency of administration of intravenous bisphosphonates so that most men are treated only once every three months, and almost always with Aredia. However, for men on hormone blockade, particularly those who might only receive a single cycle of hormone blockade, I recommend using Aredia more frequently to help prevent the development of osteoporosis. I do not recommend the use of Zometa, except in patients with definite bone metastases. For those men who do have documented bone metastases, the frequency of administration of Aredia and or Zometa is determined on an individual patient basis.
Offices seeking assistance with the following issues should contact our ZOMETA Hotline at 1-866-4ZOMETA I Carrier-Specific Coding Requirements I Alternate Reimbursement Search I Coding Questions I Patient Assistance Program PAP ; I Claim Denial Review and Reimbursement I Copay Assistance I Insurance Appeal I Letters of Medical Necessity I General Part D Information I Insurance Verification For more information contact your local Novartis Oncology Sales Specialist. ZOMETA Web site: us.zometa and imodium. The multiple event analysis demonstrated that 4 mg zometa significantly reduced the risk of developing a skeletal event by 36%compared with placebo.

Group sales up 14% to USD 20.7 billion The 14% sales increase + 9% lc ; in the first nine months of 2004 was due to strong results in both Pharmaceuticals as well as Consumer Health, where OTC and Medical Nutrition offset lower sales growth in the Sandoz generics business. Currency benefits added five percentage points in addition to seven percentage points from volumes, which was the main growth driver. Acquisitions and price increases each added one percentage point to sales growth. Pharmaceuticals sales rise 16% to USD 13.5 billion Pharmaceuticals realized double-digit sales growth for the first three quarters + 16%, + 11% lc ; , with strong performances from key brands in both the primary care and specialty medicines portfolios, leading to growth ahead of the market in all key regions, particularly the US. Volumes contributed 10 percentage points, while currency benefits added five percentage points and price increases one percentage point. Primary care product sales including mature products ; as a group were up 14% + 9% lc ; , due mainly to the expansion of the cardiovascular franchise + 21%, + 17% lc ; , which was driven by the anti-hypertensive medicines Diovan and Lotrel. Other key growth contributors were Lamisil, Trileptal, Zelnorm Zelmac, Exelon and Elidel. Specialty medicines sales comprising our activities in Oncology, Transplantation & Immunology, and Ophthalmics were up 22% + 16% lc ; and accounted for 33% of Pharmaceuticals sales versus 31% in the 2003 period. The oncology franchise reported a 27% + 21% lc ; increase for the first nine months. The key oncology drugs Gleevec Glivec, Zometa and Femara delivered dynamic growth as new data from study of these medicines continued to uncover new benefits for patients, contributing to the sales rise. Sales of the ophthalmics product Visudyne advanced 24% in USD. Excellent sales growth in the US + 12% ; was ahead of the country's prescription drugs market performance, while Japan + 18%, + 9% lc ; and Europe + 19%, + 9%lc ; achieved solid growth despite difficult market conditions. Novartis increased its share of the global healthcare market to 4.48% in the first eight months of the year, up from 4.40% in the yearago period, according to IMS Health, which reported a 7% rise in worldwide pharmaceutical sales for the first eight months of 2004. Consumer Health sales climb 10% to USD 7.1 billion Nine-month sales rose 10% + 5% lc ; , due in particular to double-digit USD sales growth in OTC and Medical Nutrition. Key products in OTC delivered solid performances, such as Lamisil Topical antifungal ; , Maalox antacid ; and Gas-X anti-gas ; , while Medical Nutrition was boosted by the Mead Johnson acquisition, which added 26 percentage points to the 38% growth of Medical Nutrition. Sandoz suffered from comparative base effects after strong growth in 2003 due to the launch of the antibiotic AmoxC as well as from competitive pricing pressures, which resulted in growth of 2% in USD and a decline of 3% in local currencies. An overall increase in Consumer Health volumes contributed two percentage points, currencies added five percentage points while prices added one percentage point and acquisitions two percentage points to sales growth and colace.
1. Insull W, Davidson MH, Demke DM, et al. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis 1995; 112: 223-35. 1. The ASA American Society of Anesthesiologists ; physical status classification has been shown to generally correlate with the perioperative mortality rate mortality rates given below ; . 2. ASA 1: a normal healthy patient 0.06-0.08% ; . 3. ASA 2: a patient with a mild systemic disease mild diabetes, controlled hypertension, obesity [0.27-0.4%] ; . 4. ASA 3: a patient with a severe systemic disease that limits activity angina, COPD, prior myocardial infarction [1.8-4.3%] ; . 5. ASA 4: a patient with an incapacitating disease that is a constant threat to life CHF, renal failure [7.8-23%] ; . 6. ASA 5: a moribund patient not expected to survive 24 hours ruptured aneurysm [9.4-51%] ; . 7. ASA 6: brain-dead patient whose organs are being harvested. 8. For emergent operations, add the letter `E' after the classification and depakote. O011 Characterizing Dizziness After Head Trauma M. E. Hoffer, K. R. Gottshall, R. Moore, B. J. Balough, D. C. Wester Otolaryngology, Naval Medical Center San Diego, San Diego, United States Background: Traumatic brain injury TBI ; is the second most common of all neurological disorder with an incidence of greater than 180 100, 000. Current world affairs, stronger athletes, and faster and larger motorized vehicles have resulted in an increase in the rate of head trauma over the last several years. Temporary and permanent disability due to CHI which is often related to vestibular disorders can be devastating to the individual, their family, and their workplaces. Unfortunately little evidence is available characterizing dizziness after TBI. The nature of our treatment facility has given us the ability to evaluate, study, and treat one of the largest populations of head trauma patients. Objectives: This study had two objectives. We first characterized the dizziness associated with TBI and then examined the therapeutic results of vestibular rehabilitation both with respect to passive and active measures of function. Methods: Individuals identified with TBI and presenting with vestibular symptoms were evaluated utilizing a standard test battery. The test battery included a detailed otolaryngologic history and physical exam, dynamic computerized posturography, rotational chair testing, and dynamic visual acuity testing. In addition, individuals were scored for a Dynamic Gait Index DGI ; and administered the Dizziness Handicapped Index DHI ; and the Activities Specific Balance Confidence Scale ABC ; surveys. The test battery was administered before, during, and after treatment. Results: Over one hundred individuals suffering from dizziness after head injury and presenting to our clinic in a one year period of time were divided into three diagnostic groups. In mild head trauma patients 41% of the individuals suffered from post-traumatic vestibular migraines, 28% of the individuals had post-traumatic positional vertigo, and 19% of the individuals were classified as post-traumatic spatial disorientation. The remaining 12% of the patients could not be characterized. The positional group had objective physical exam findings, which cleared with treatment in all cases. 84% of the migraine group demonstrated an improvement of their vestibular test results as compared to 27% of the disorientation group. Mean time to return to work was less than 1 week for the positional group, 3.8 weeks for the migraine group, and greater than 3 months for the disorientation group. A higher percentage of indi. 1135U Chlorophenols, Urine Specimen Requirements: Specimen Requirements: 3 ml Urine Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection Required: Not Required Special Handling: Collect sample at end of shift. Rejection Criteria: None Stability: Room Temperature: Undetermined Refrigerated: Undetermined Frozen -20 C ; : Undetermined Summary of Changes: Refrigerated requirement was added. 1140B Chloroquine, Blood Specimen Requirements: Specimen Requirements: 2 ml Blood Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection Required: Not Required Special Handling: None Rejection Criteria: None Stability: Room Temperature: Undetermined Refrigerated: Undetermined Frozen -20 C ; : Undetermined Summary of Changes: Refrigerated requirement was added. 1140FL Chloroquine, Fluid Specimen Requirements: Specimen Requirements: 5 ml Fluid Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection Required: Not Required Special Handling: None Rejection Criteria: None Stability: Room Temperature: Undetermined Refrigerated: Undetermined Frozen -20 C ; : Undetermined Summary of Changes: Refrigerated requirement was added and imuran!

In a randomized trial, the FOOD Feed Or Ordinary Diet ; Trial Collaboration is testing the utility of several feeding strategies including oral supplementation, early versus delayed nasogastric tube feeding, and nasogastric versus percutaneous endoscopic gastrostomy feeding. A preliminary report based on 3012 patients indicates that poor baseline nutritional status is associated with worse outcomes at 6 months.64 Although weakened, this relationship persists after adjustment for other factors including the patient's age.

These patients had recent invasive dental procedures. In response to reports of ONJ in cancer patients treated with IV bisphosphonates, changes were made to the labels of Zometa and Aredia. The Adverse Events section was updated to include ONJ in September of 2003 for Zometa, and then Aredia in October. The Precautions section.

Table 5. Grade 4 Laboratory Abnormalities for Serum Creatinine, Serum Calcium, Serum Phosphorus, and Serum Magnesium in Two Clinical Trials in Patients with HCM Grade 4 Laboratory Parameter Zometa 4 mg Pamidronate 90 mg n N % ; n N % ; Serum Creatinine1 0 86 -- 1 100 1% ; Hypocalcemia2 0 86 -- 0 100 -- 1 70 1% ; 4 Hypophosphatemia3 Hypomagnesemia4 0 71 -- 1 1Grade 3 Upper Limit of Normal Grade 4 6x Upper Limit of Normal ; 2Grade 3 7 mg dL Grade 4 6 mg dL ; 3Grade 3 2 mg dL Grade 4 1 mg dL ; 4Grade 3 0.8 mEq L Grade 4 0.5 mEq L ; Injection Site Reactions: Local reactions at the infusion site, such as redness or swelling, were observed infrequently. In most cases, no specific treatment is required and the symptoms subside after 24-48 hours. Ocular Adverse Events: Ocular inflammation such as uveitis and scleritis can occur with bisphosphonate use. No cases of iritis, scleritis or uveitis were reported during these clinical trials. Multiple Myeloma and Bone Metastases of Solid Tumors: The safety analysis includes patients treated in the core and extension phases of the trials. The analysis includes the 2, 042 patients treated with Zometa 4 mg, pamidronate 90 mg or placebo in the three controlled multicenter bone metastases trials, including 969 patients completing the efficacy phase of the trial, and 619 patients that continued in the safety extension phase. Only 347 patients completed the extension phases and were followed for two years or 21 months for the other solid tumor patients ; . The median duration of exposure for safety analysis for Zometa 4 mg core plus extension phases ; was 12.8 months for breast cancer and multiple myeloma, 10.8 months for prostate cancer, and 4.0 months for other solid tumors. Table 6 describes adverse events that were reported by 10% of patients. Adverse events are listed regardless of presumed causality to study drug. Table 6. Percentage of Patients with Adverse Events 10% Reported in Three Bone Metastases Clinical Trials by Body System Zometa Pamidronate Placebo 4 mg 90 mg n % ; n % ; n % ; Patients Studied Total No. of Patients 1031 100 ; 556 100 ; 455 100 ; Total No. of Patients with any AE 1015 98 ; 548 99 ; 445 98 ; Blood and Lymphatic Anemia 344 33 ; 175 32 ; 128 28 ; Neutropenia 124 12 ; 83 15 ; Thrombocytopenia 102 10 ; 53 10 ; Gastrointestinal Nausea 476 46 ; 266 48 ; 171 38 ; Vomiting 333 32 ; 183 33 ; 122 27 ; Constipation 320 31 ; 162 29 ; 174 38 ; Diarrhea 249 24 ; 162 29 ; 83 18 ; Abdominal Pain 143 14 ; 81 15 ; Dyspepsia 105 10 ; 74 13 ; Stomatitis 86 8 ; 65 Sore Throat 82 8 ; 61 General Disorders and Administration Site Fatigue 398 39 ; 240 43 ; 130 29 ; Pyrexia 328 32 ; 172 31 ; 89 20 ; Weakness 252 24 ; 108 19 ; 114 25 ; Edema Lower Limb 215 21 ; 126 23 ; 84 19 ; Rigors 112 11 ; 62 11 ; continued.

Zometa price